Previous 10 | Next 10 |
home / stock / mrna / mrna articles
Shares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease experts predict a small rise in COVID-19 cases ...
Shares of XP Inc. (NASDAQ:XP) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results...
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of Analog Devices, Inc. (NASDAQ:ADI) rose s...
Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with&n...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
On CNBC's “Mad Money Lightning Round,” Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA). On May 14, Evercore ISI Group analyst C...
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 27.7% on an annualized basis producing an average annual return of 40.43...
The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:MRNA) on Friday that its review of a new vaccine has been delayed. The agency...
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...